A14377 Nephrotoxicity of Iodixanol Versus Iopamidol in Patients Undergoing Renal Artery Stenting

Objectives: To compare the nephrotoxic effects of iodixanol and iopamidol in patients undergoing renal artery stenting. Methods: Patients scheduled for renal artery stenting were randomly assigned to the iodixanol group (n = 143) and iopamidol group (n = 140). The primary endpoint was the incidence of contrast-induced acute kidney injury (CM-AKI), which was defined as an increase ≥25% or ≥44.2 μmol/l (0.5 mg/dl) in serum creatinine (SCr) from baseline within 72 h after receiving contrast media (CM). The secondary endpoints were the mean peak estimated glomerular filtration rate (eGFR) decrease within 72 h after receiving CM and major adverse renal events (SCr increased by two times after 30 days, the need for dialysis treatment, rehospitalization for acute renal failure or kidney-related death) during hospitalization and within 30 days postdischarge. Results: The incidence of CM-AKI did not differ significantly between the iodixanol group and iopamidol group (19.1% vs 18.3%; p = 0.870). There was no significant difference in the mean peak eGFR decrease between the iodixanol group and iopamidol group (10.3 ± 11.4 vs 11.5 ± 12.7 ml/min*1.73 m2, p = 0.384). There were 2 patients [1 (0.7%) patient in the iodixanol group and 1 (0.7%) patients in the iopamidol group] with doubling of SCr; no other adverse renal events were observed. Conclusion: Our data showed that the nephrotoxicity of iodixanol was comparable with that of iopamidol in patients undergoing renal artery stenting.